Does the media prefer ELAN or ELVN?

In the previous week, Elanco Animal Health had 10 more articles in the media than Enliven Therapeutics. MarketBeat recorded 23 mentions for Elanco Animal Health and 13 mentions for Enliven Therapeutics. Elanco Animal Health's average media sentiment score of 0.89 beat Enliven Therapeutics' score of 0.67 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 9 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enliven Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ELVN or ARWR?

In the previous week, Arrowhead Pharmaceuticals had 4 more articles in the media than Enliven Therapeutics. MarketBeat recorded 17 mentions for Arrowhead Pharmaceuticals and 13 mentions for Enliven Therapeutics. Arrowhead Pharmaceuticals' average media sentiment score of 0.70 beat Enliven Therapeutics' score of 0.67 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to AXSM or ELVN?

In the previous week, Enliven Therapeutics had 2 more articles in the media than Axsome Therapeutics. MarketBeat recorded 13 mentions for Enliven Therapeutics and 11 mentions for Axsome Therapeutics. Enliven Therapeutics' average media sentiment score of 0.67 beat Axsome Therapeutics' score of 0.44 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Enliven Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, ELVN or ABVX?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A Abivax N/A N/A -$380.27M -$5.21 N/A

Is ELVN or ABVX more profitable?

Enliven Therapeutics' return on equity of -21.04% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Enliven Therapeutics N/A -21.04% -20.41% Abivax N/A -99.02% -70.26%

Does the media prefer ELVN or ABVX?

In the previous week, Enliven Therapeutics had 4 more articles in the media than Abivax. MarketBeat recorded 13 mentions for Enliven Therapeutics and 9 mentions for Abivax. Abivax's average media sentiment score of 1.45 beat Enliven Therapeutics' score of 0.67 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ELVN or KRYS?

In the previous week, Krystal Biotech had 18 more articles in the media than Enliven Therapeutics. MarketBeat recorded 31 mentions for Krystal Biotech and 13 mentions for Enliven Therapeutics. Krystal Biotech's average media sentiment score of 1.00 beat Enliven Therapeutics' score of 0.67 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 11 Very Positive mention(s) 7 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Enliven Therapeutics (ELVN) Competitors

$60.27 +0.57 (+0.95%)

Closing price 04:00 PM Eastern

Extended Trading

$60.30 +0.03 (+0.05%)

As of 04:20 PM Eastern

Compare

ELVN vs. ELAN, ARWR, AXSM, ABVX, and KRYS

Should you buy Enliven Therapeutics stock or one of its competitors? MarketBeat compares Enliven Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enliven Therapeutics include Elanco Animal Health (ELAN), Arrowhead Pharmaceuticals (ARWR), Axsome Therapeutics (AXSM), Abivax (ABVX), and Krystal Biotech (KRYS).

How does Enliven Therapeutics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Enliven Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Enliven Therapeutics	N/A	-21.04%	-20.41%

Enliven Therapeutics has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$5.02B	2.41	-$232M	-$0.50	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

Elanco Animal Health has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

Elanco Animal Health currently has a consensus price target of $29.09, indicating a potential upside of 20.07%. Enliven Therapeutics has a consensus price target of $72.67, indicating a potential upside of 20.57%. Given Enliven Therapeutics' higher possible upside, analysts plainly believe Enliven Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Elanco Animal Health had 10 more articles in the media than Enliven Therapeutics. MarketBeat recorded 23 mentions for Elanco Animal Health and 13 mentions for Enliven Therapeutics. Elanco Animal Health's average media sentiment score of 0.89 beat Enliven Therapeutics' score of 0.67 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	9 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enliven Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by company insiders. Comparatively, 3.0% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Elanco Animal Health beats Enliven Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Enliven Therapeutics compare to Arrowhead Pharmaceuticals?

Enliven Therapeutics (NASDAQ:ELVN) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Enliven Therapeutics presently has a consensus target price of $72.67, suggesting a potential upside of 20.57%. Arrowhead Pharmaceuticals has a consensus target price of $97.33, suggesting a potential upside of 13.40%. Given Enliven Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Enliven Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

In the previous week, Arrowhead Pharmaceuticals had 4 more articles in the media than Enliven Therapeutics. MarketBeat recorded 17 mentions for Arrowhead Pharmaceuticals and 13 mentions for Enliven Therapeutics. Arrowhead Pharmaceuticals' average media sentiment score of 0.70 beat Enliven Therapeutics' score of 0.67 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Enliven Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Enliven Therapeutics' return on equity of -21.04% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
Arrowhead Pharmaceuticals	-47.79%	-57.65%	-18.26%

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Arrowhead Pharmaceuticals has higher revenue and earnings than Enliven Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Arrowhead Pharmaceuticals	$829.45M	14.58	-$1.63M	-$2.15	N/A

Enliven Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

Summary

Arrowhead Pharmaceuticals beats Enliven Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Enliven Therapeutics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 3.0% of Enliven Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Axsome Therapeutics has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

Axsome Therapeutics currently has a consensus price target of $265.55, indicating a potential upside of 26.37%. Enliven Therapeutics has a consensus price target of $72.67, indicating a potential upside of 20.57%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Axsome Therapeutics is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.91
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Enliven Therapeutics had 2 more articles in the media than Axsome Therapeutics. MarketBeat recorded 13 mentions for Enliven Therapeutics and 11 mentions for Axsome Therapeutics. Enliven Therapeutics' average media sentiment score of 0.67 beat Axsome Therapeutics' score of 0.44 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enliven Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enliven Therapeutics has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	16.94	-$183.17M	-$3.73	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

Enliven Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Enliven Therapeutics' return on equity of -21.04% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Enliven Therapeutics	N/A	-21.04%	-20.41%

Summary

Enliven Therapeutics beats Axsome Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Enliven Therapeutics compare to Abivax?

Enliven Therapeutics (NASDAQ:ELVN) and Abivax (NASDAQ:ABVX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

Enliven Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, Abivax has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

Enliven Therapeutics' return on equity of -21.04% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
Abivax	N/A	-99.02%	-70.26%

Enliven Therapeutics currently has a consensus target price of $72.67, indicating a potential upside of 20.57%. Abivax has a consensus target price of $156.50, indicating a potential upside of 20.38%. Given Enliven Therapeutics' higher possible upside, analysts plainly believe Enliven Therapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 3.0% of Enliven Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Enliven Therapeutics had 4 more articles in the media than Abivax. MarketBeat recorded 13 mentions for Enliven Therapeutics and 9 mentions for Abivax. Abivax's average media sentiment score of 1.45 beat Enliven Therapeutics' score of 0.67 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Enliven Therapeutics beats Abivax on 8 of the 13 factors compared between the two stocks.

How does Enliven Therapeutics compare to Krystal Biotech?

Enliven Therapeutics (NASDAQ:ELVN) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by company insiders. Comparatively, 13.1% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Krystal Biotech has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Krystal Biotech	$389.13M	24.55	$204.83M	$7.98	40.44

Enliven Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

Krystal Biotech has a net margin of 54.82% compared to Enliven Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 19.34% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
Krystal Biotech	54.82%	19.34%	17.65%

Enliven Therapeutics presently has a consensus price target of $72.67, suggesting a potential upside of 20.57%. Krystal Biotech has a consensus price target of $361.56, suggesting a potential upside of 12.04%. Given Enliven Therapeutics' higher probable upside, research analysts plainly believe Enliven Therapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.92

In the previous week, Krystal Biotech had 18 more articles in the media than Enliven Therapeutics. MarketBeat recorded 31 mentions for Krystal Biotech and 13 mentions for Enliven Therapeutics. Krystal Biotech's average media sentiment score of 1.00 beat Enliven Therapeutics' score of 0.67 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	11 Very Positive mention(s)	7 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Krystal Biotech beats Enliven Therapeutics on 14 of the 16 factors compared between the two stocks.

Get Enliven Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELVN vs. The Competition

Export

Metric	Enliven Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.67B	$3.61B	$6.93B	$12.84B
Dividend Yield	N/A	3.77%	2.60%	9.78%
P/E Ratio	-36.09	7.68	281.16	25.43
Price / Sales	N/A	1,229.81	577.53	82.47
Price / Cash	N/A	103.01	71.79	50.79
Price / Book	7.79	17.03	12.86	6.06
Net Income	-$103.69M	-$12.50M	$3.49B	$348.34M
7 Day Performance	11.71%	2.90%	2.64%	3.03%
1 Month Performance	20.52%	-4.49%	-2.64%	-3.04%
1 Year Performance	219.90%	54.14%	76.00%	20.65%

Enliven Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELVN Enliven Therapeutics	2.6021 of 5 stars	$60.27 +1.0%	$72.67 +20.6%	+210.6%	$3.67B	N/A	N/A	50	News Coverage Earnings Report Analyst Forecast
ELAN Elanco Animal Health	3.9704 of 5 stars	$25.53 +0.5%	$28.73 +12.5%	+84.0%	$12.75B	$4.89B	N/A	9,400	Trending News Earnings Report Analyst Forecast
ARWR Arrowhead Pharmaceuticals	2.07 of 5 stars	$85.78 +0.3%	$95.08 +10.8%	+427.7%	$12.08B	$829.45M	N/A	400	Earnings Report Analyst Forecast
AXSM Axsome Therapeutics	3.6438 of 5 stars	$234.20 -1.7%	$261.48 +11.6%	+105.5%	$12.05B	$638.50M	N/A	380	Positive News Upcoming Earnings
ABVX Abivax	3.6928 of 5 stars	$124.23 -2.9%	$156.50 +26.0%	+76.8%	$10.83B	N/A	N/A	61	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELVN) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enliven Therapeutics (ELVN) Competitors

ELVN vs. ELAN, ARWR, AXSM, ABVX, and KRYS

How does Enliven Therapeutics compare to Elanco Animal Health?

Summary

How does Enliven Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Enliven Therapeutics compare to Axsome Therapeutics?

Summary

How does Enliven Therapeutics compare to Abivax?

Summary

How does Enliven Therapeutics compare to Krystal Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELVN vs. The Competition

Enliven Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enliven Therapeutics (ELVN) Competitors

ELVN vs. ELAN, ARWR, AXSM, ABVX, and KRYS

How does Enliven Therapeutics compare to Elanco Animal Health?

Is ELAN or ELVN more profitable?

Which has stronger valuation & earnings, ELAN or ELVN?

Which has more risk and volatility, ELAN or ELVN?

Do analysts prefer ELAN or ELVN?

Does the media prefer ELAN or ELVN?

Do institutionals & insiders believe in ELAN or ELVN?

Summary

How does Enliven Therapeutics compare to Arrowhead Pharmaceuticals?

Do analysts rate ELVN or ARWR?

Does the media favor ELVN or ARWR?

Is ELVN or ARWR more profitable?

Do institutionals and insiders believe in ELVN or ARWR?

Which has better earnings & valuation, ELVN or ARWR?

Which has more risk & volatility, ELVN or ARWR?

Summary

How does Enliven Therapeutics compare to Axsome Therapeutics?

Do insiders & institutionals hold more shares of AXSM or ELVN?

Which has more volatility and risk, AXSM or ELVN?

Do analysts prefer AXSM or ELVN?

Does the media refer more to AXSM or ELVN?

Which has stronger valuation and earnings, AXSM or ELVN?

Is AXSM or ELVN more profitable?

Summary

How does Enliven Therapeutics compare to Abivax?

Which has more volatility and risk, ELVN or ABVX?

Is ELVN or ABVX more profitable?

Do analysts prefer ELVN or ABVX?

Which has higher valuation and earnings, ELVN or ABVX?

Do institutionals & insiders believe in ELVN or ABVX?

Does the media prefer ELVN or ABVX?

Summary

How does Enliven Therapeutics compare to Krystal Biotech?

Do institutionals and insiders hold more shares of ELVN or KRYS?

Which has higher valuation & earnings, ELVN or KRYS?

Which has more risk & volatility, ELVN or KRYS?

Is ELVN or KRYS more profitable?

Do analysts rate ELVN or KRYS?

Does the media prefer ELVN or KRYS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELVN vs. The Competition

Enliven Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools